Abbott Supports Relief Efforts in Haiti

The Abbott Fund provided $150,000 in grants to advance relief efforts

Hurricane Matthew, one of the strongest hurricanes seen in recent years, has had a devastating impact on Haiti and damaged the U.S. Southeast coast as well. The Abbott Fund (Abbott is No. 14 on the DiversityInc Top 50 Companies list) provided $75,000 in funding to help our longstanding partner in Haiti, Partners In Health (PIH), to meet critical health needs in the country.


In the U.S., the Abbott Fund provided a $75,000 grant to the American Red Cross to help provide emergency shelter, food, blankets and supplies to thousands of people across Florida, Georgia, North and South Carolina, and Virginia.

In Haiti, the Abbott Fund grant will be used to ramp up local production of PIH's Nourimanba, a life-saving treatment for severe malnutrition that is provided to children at PIH's healthcare facilities in Haiti. Nourimanba is produced by PIH's sister organization, Zanmi Lasante, at the Nourimanba Production Facility (SPN, or Sant Prodiksyon Nourimanba in Haitian Creole) in Central Haiti.

Opened in 2013, the SPN facility was built through a partnership between Abbott, the Abbott Fund, PIH and ZL, with the close involvement of Abbott scientists, engineers and other experts. Built to withstand hurricanes, the facility has quickly resumed operations to continue production of Nourimanba. The Abbott Fund grant will be used to purchase the necessary raw materials and supplies to expand production in the coming days, in order to meet the expected increased demand for Nourimanba following the hurricane.

For more information on how Partners In Health is addressing the impact of Hurricane Matthew, and to donate to advance their important work in Haiti, click here.

For more information on the SPN facility in Haiti, and the longstanding partnership between Abbott, the Abbott Fund, PIH and ZL to help meet health needs and drive economic development in the region, visit partnershipinhaiti.org.

Abbott: Connected Devices Turn Data Into Better Health

Abbott's Robert Ford Joins a Panel Discussing the Potential for Connected Medical Devices to Improve Patient Care and Drive Better Outcomes.

Originally Published by Abbott.

Today's medical devices are creating terabytes of information that gives patients, doctors and health providers real-time insight into someone's vital statistics, heart health and even bloodwork.

But can all this new information really make someone healthier?

Read More Show Less

Abbott Introduces the Afinion™ 2 Analyzer Rapid Test System for Diabetes Management

State-of-the-art multi-assay test system helps people with diabetes get the HbA1c results they need within three minutes — allowing more time for consultation and care during a single healthcare visit.

Originally Published by Abbott.

Abbott announced the launch of its Afinion™ 2 analyzer in the U.S., the newest generation of the Afinion test system. The Afinion 2 builds on Abbott's heritage in diabetes care by empowering patients with information about their health that they can discuss with their providers during a single visit.

Read More Show Less

Abbott's Xience Sierra Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease

Coronary artery disease is the most common form of heart disease, which is the second leading cause of death in Japan.

Originally Published by Abbott.

Abbott announced that Japan's Ministry of Health Labour and Welfare (MHLW) granted national reimbursement for XIENCE Sierra™, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent. XIENCE Sierra improves upon previous versions of XIENCE with an enhanced stent design, a new delivery system, and unique sizes to help doctors treat challenging cases.

XIENCE Sierra was designed to help doctors more easily treat people with difficult-to-treat blockages that involve multiple or totally blocked arteries or complications such as diabetes. Complex cases are increasingly prevalent as people with coronary artery disease are living longer.

"Extensive clinical data and 10 years of real-world experience with the XIENCE family of stents provide doctors with confidence that they are treating their patients with one of the safest stents available," said Chuck Brynelsen, senior vice president of Abbott's vascular business. "National reimbursement of XIENCE Sierra will provide people in Japan with greater access to this life-changing technology that can help them live their best lives."

Coronary artery disease is the most common form of heart disease, which is the second leading cause of death in Japan. National reimbursement in Japan will enable doctors to treat more patients with XIENCE Sierra through the country's health insurance plans. XIENCE Sierra was approved in Japan on April 4, 2018, received CE Mark in Europe late last year, and is under review with the U.S. Food and Drug Administration.

XIENCE has been studied in over 100 clinical trials and in 10 years of global real-world experience. Its safety profile is unprecedented with consistent low rates of stent thrombosis, even in complex cases. More than eight million people worldwide have received a XIENCE stent since its initial regulatory approval.